Browse our 650+ Publications​

Latest Publications

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Dimopoulos M, et al.
Blood Advances
October 2024
Authors and Affiliates
Meletios A. Dimopoulos,1 Daniel Coriu,2,3 Sosana Delimpasi,4 Ivan ˇ Spiˇcka,5 Terry Upchurch,6 Belle Fang,6 Rakhshandra Talpur,6 Edward Faber,7 Meral Beksac,8 and Xavier Leleu9 1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania; 3Department of Haematology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; 4Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece; 5First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic; 6Amgen Inc, Thousand Oaks, CA; 7Oncology Hematology Care, Inc, Cincinnati, OH; 8Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey; and 9Department of Hematology and Cellular Therapy, CIC U1402 CHU de Poitiers, Poitiers, France

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity(MRD2STOP)

Derman B, et al.
Blood Cancer Journal
October 2024
Authors and Affiliates
Benjamin A. Derman1✉, Ajay Major 2, Jennifer Cooperrider1, Ken Jiang1, Aubrianna Ramsland1, Theodore Karrison3, Tadeusz Kubicki 1 and Andrzej J. Jakubowiak1 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. 2Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. 3Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Sidana S, et al.
Blood
October 2024
Authors and Affiliates
Surbhi Sidana1*, Krina K. Patel2*, Lauren C. Peres*3, Radhika Bansal4, Mehmet H. Kocoglu5, Leyla Shune6, Shebli Atrash7, Kinaya Smith8, Shonali Midha9, Christopher Ferreri,7, Binod Dhakal8, Danai Dima10, Patrick Costello9, Charlotte Wagner11, Ran Reshef12, Hitomi Hosoya1, Lekha Mikkilineni1, Djordje Atanackovic5, Saurabh Chhabra13, Ricardo Parrondo14, Omar Nadeem9, Hashim Mann,15 Nilesh Kalariya2, Vanna Hovanky1, Gabriel De Avila3, Ciara L Freeman3, Frederick L. Locke3, Melissa Alsina3, Sandy Wong16, Megan Herr17, Myo Htut18, Joseph McGuirk6, Douglas W. Sborov11, Jack Khouri10, Thomas Martin16, Murali Janakiram18*, Yi Lin4*, and Doris K. Hansen3* *S.S, K.K.P, L.C.P are co-first authors; M.J, Y.L, and D.K.H are co-senior authors. Affiliations: 1. Stanford University School of Medicine 2. The University of Texas MD Anderson Cancer Center, 3. Moffitt Cancer Center, 4. Mayo Clinic, Rochester, 5. University of Maryland School of Medicine, 6. University of Kansas Medical Center, 7. Levine Cancer Institute, 8. Medical College of Wisconsin, 9. Dana-Farber Cancer Institute, 10. Cleveland Clinic Taussig Cancer Center. 11. Huntsman Cancer Institute at the University of Utah, 12. Columbia University Irving Medical Center, 13. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, 14. Mayo Clinic, Jacksonville 15. Virginia Commonwealth University, 16. University of California San Francisco, 17. Rosewell Park Cancer Center, 18. City of Hope Comprehensive Cancer Center,

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Badros A, et al.
Blood
September 2024
Authors and Affiliates
Ashraf Badros,1 Laahn Foster,2 Larry D. Anderson Jr,3 Chakra P. Chaulagain,4 Erin Pettijohn,5 Andrew J. Cowan,6 Caitlin Costello,7 Sarah Larson,8 Douglas W. Sborov,9 Kenneth H. Shain,10 Rebecca Silbermann,11 Nina Shah,12* Alfred Chung,12 Maria Krevvata,13 Huiling Pei,14 Sharmila Patel,15 Vipin Khare,15 Annelore Cortoos,15 Robin Carson,13 Thomas S. Lin,15 and Peter Voorhees16 1Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United States; 2Division of Hematology Oncology, University of Virginia, Charlottesville, VA, United States; 3Myeloma, Waldenstrom’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States; 4Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, FL, United States; 5Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, United States; 6Division of Medical Oncology, Fred Hutch Cancer Center/University of Washington, Seattle, WA, United States; 7Moores Cancer Center, University of California San Diego, La Jolla, CA, United States; 8Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; 9Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States; 10Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, United States; 11Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States; 12Department of Medicine, University of California San Francisco, San Francisco, CA, United States; 13Janssen Research & Development, LLC, Spring House, PA, United States; 14Janssen Research & Development, LLC, Titusville, NJ, United States; 15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, United States; 16Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, United States.

Epcoritamab in relapsed/refractory large B-cell lymphoma:2-year follow-up from the pivotal EPCORE NHL-1 trial

Thieblemont C, et al.
Leukemia
September 2024
Authors and Affiliates
Catherine Thieblemont 1✉, Yasmin H. Karimi2, Herve Ghesquieres3, Chan Y. Cheah4, Michael Roost Clausen5, David Cunningham6, Wojciech Jurczak 7, Young Rok Do8, Robin Gasiorowski 9, David John Lewis10, Tae Min Kim 11, Marjolein van der Poel12, Michelle Limei Poon13, Tatyana Feldman14, Kim M. Linton15, Anna Sureda 16, Martin Hutchings17, Minh H. Dinh 18, Nurgul Kilavuz19, David Soong19, Thomas Mark20, Mariana Sacchi19, Tycel Phillips21,23 and Pieternella J. Lugtenburg22 1Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. 2Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 3Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 4Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia. 5Vejle Hospital, Vejle, Denmark. 6The Royal Marsden NHS Foundation Trust, Sutton, UK. 7MSC National Research Institute of Oncology, Kraków, Poland. 8Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. 9Concord Hospital, University of Sydney, Sydney, Australia. 10University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK. 11Seoul National University Hospital, Seoul, Republic of Korea. 12Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 13National University Hospital, Singapore, Singapore. 14John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA. 15The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK. 16Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. 17Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. 18AbbVie, North Chicago, IL, USA. 19Genmab, Plainsboro, NJ, USA. 20Genmab, Copenhagen, Denmark. 21University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. 22Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands. 23Present address: City of Hope, Duarte, CA, USA. ✉email: catherine.thieblemont@aphp.fr

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial

Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio, Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD); Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy

Longitudinal study of immunity to SARS-CoV2 inocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination

Kister I., et al.
Annals of Clinical and Translational Neurology
August 2024
Authors and Affiliates
Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard & Gregg J. Silverman

Case report of fatal immune-mediatedmyocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependentCD28 costimulator and dualPD-L1/CTLA-4checkpoint inhibitor, incombination with pembrolizumab

Cavalcante L., et al.
Journal for ImmunoTherapy of Cancer
August 2024
Authors and Affiliates
Ludimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar.

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Touzeau C, et al.
Blood
August 2024
Authors and Affiliates
Cyrille Touzeau (University hospital, France) Amrita Krishnan (City of Hope Comprehensive Cancer Center, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France) Aurore Perrot (CHU Toulouse - IUCT Oncopole, France) Saad Usmani (Memorial Sloan Kettering Cancer Center, United States) Salomon Manier (CHU Lille, France) Michele Cavo (Seràgnoli Institute of Hematology; Bologna University School of Medicine, Bologna, Italy, Italy) Carmen Martinez Chamorro (Hospital Universitario Quirón Pozuelo, Spain) Ajay Nooka (Emory University Winship Cancer Institute, United States) Thomas Martin (UCSF, United States) Lionel Karlin (Hôpital Lyon Sud, France) Xavier Leleu (Hopital La Miletrie, France) Nizar Bahlis (Arnie Charbonneau Cancer Institute, University of Calgary, Canada) Britta Besemer (University Hospital of Tuebingen, Germany) Lixia Pei (Janssen R&D, United States) Sarah Stein (Janssen R&D US, United States) Shun Xin Wang Lin (Janssen Research & Development, United States) Danielle Trancucci (Janssen Research & Development, United States) Raluca Verona (Janssen Research & Development, United States) Suzette Girgis (Janssen Research & Development, LLC, United States) Xin Miao (Janssen Research & Development, LLC, United States) Clarissa Uhlar (Janssen R&D, United States) Katherine Chastain (Janssen Research & Development, LLC, United States) Alfred Garfall (University of Pennsylvania, United States)

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Martinez-Lopez J, et al.
Blood Cancer Journal
August 2024
Authors and Affiliates
J. Martinez-Lopez 1,2, N. Lopez-Muñoz 1, A. Chari 2, S. Dorado 3, S. Barrio1, S. Arora2, A. Kumar2, A. Chung2, T. Martin 2 and J. Wolf2 1Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. 2Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 3Medical Department, Altum Sequencing, Madrid, Spain.
Previous Next